Assessment of Whether the American Society of Clinical Oncology’s Value Framework and the European Society for Medical Oncology’s Magnitude of Clinical Benefit Scale Measure Absolute or Relative Clinical Survival Benefit: An Analysis of Randomized Clinical Trials

Documenti analoghi

• Clinical benefits of precision medicine in treating solid cancers: European Society of Medical Oncology-Magnitude of Clinical Benefit Scale score-based analysis
  di: Hibino, Y., et al.
  Pubblicazione: (2021)
• Comparison of Long-term Survival Benefits in Trials of Immune Checkpoint Inhibitor vs Non–Immune Checkpoint Inhibitor Anticancer Agents Using ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale
  di: Everest, Louis, et al.
  Pubblicazione: (2019)
• Assessment of Food and Drug Administration– and European Medicines Agency–Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review
  di: Arciero, Vanessa, et al.
  Pubblicazione: (2021)
• The European Society for Medical Oncology Magnitude of Clinical Benefit Scale in daily practice: a single institution, real-life experience at the Medical University of Vienna
  di: Kiesewetter, Barbara, et al.
  Pubblicazione: (2016)
• The European Society for Medical Oncology 'Magnitude of Clinical Benefit Scale' field-tested in infrequent tumour entities: an extended analysis of its feasibility at the Medical University of Vienna
  di: Kiesewetter, Barbara, et al.
  Pubblicazione: (2017)